HIV-prevention drug to cost $40 a year from 2027

The two organizations have signed separate agreements with Indian pharmaceutical companies to produce cheaper generics of lenacapavir - a twice-yearly injection shown to reduce the risk of HIV transmission by more than 99.9% - for low- and middle-income countries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RF2o8l5
via IFTTT